Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Insights into the leveraging of GABAergic signaling in cancer therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Author(s): Li TJ;Li TJ; Jiang J; Jiang J; Tang YL; Tang YL; Liang XH; Liang XH
  • Source:
    Cancer medicine [Cancer Med] 2023 Jul; Vol. 12 (13), pp. 14498-14510. Date of Electronic Publication: 2023 May 18.
  • Publication Type:
    Journal Article; Review; Research Support, Non-U.S. Gov't
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE
    • Publication Information:
      Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-
    • Subject Terms:
      Signal Transduction* ; gamma-Aminobutyric Acid*/metabolism ; gamma-Aminobutyric Acid*/pharmacology; Animals ; Humans ; Extracellular Signal-Regulated MAP Kinases/metabolism ; Carcinogenesis/metabolism ; Cell Line, Tumor ; Mammals/metabolism ; Tumor Microenvironment
    • Abstract:
      Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the brain of adult mammals. Several studies have demonstrated that the GABAergic system may regulate tumor development via GABA receptors, downstream cyclic adenosine monophosphate (cAMP) pathway, epithelial growth factor receptor (EGFR) pathway, AKT pathway, mitogen-activated protein kinase (MAPK) or extracellular signal-related kinases (ERK) pathway, and matrix metalloproteinase (MMP) pathway, although the exact mechanism is unclear. Pioneering studies reported that GABA signaling exists and functions in the cancer microenvironment and has an immunosuppressive effect that contributes to metastasis and colonization. This article reviews the molecular structures and biological functions of GABAergic components correlated with carcinogenesis, the mechanisms underlying GABAergic signaling that manipulate the proliferation and invasion of cancer cells, and the potential GABA receptor agonists and antagonists for cancer therapy. These molecules may provide an avenue for the development of specific pharmacological components to prevent the growth and metastasis of various cancers.
      (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
    • References:
      J Gastroenterol Hepatol. 2009 Apr;24(4):688-96. (PMID: 19032445)
      J Pain. 2017 Aug;18(8):933-946. (PMID: 28323246)
      Molecules. 2020 Jul 07;25(13):. (PMID: 32646032)
      Dig Dis. 1993;11(1):45-54. (PMID: 8383020)
      Mol Pharmacol. 2017 Sep;92(3):265-277. (PMID: 28424220)
      Neuropharmacology. 2005 Mar;48(3):343-53. (PMID: 15721166)
      Cancer Res. 2003 Dec 1;63(23):8090-6. (PMID: 14678958)
      Life Sci. 2008 Feb 27;82(9-10):536-41. (PMID: 18222491)
      Mol Cell Endocrinol. 2014 Mar 5;383(1-2):69-79. (PMID: 24296312)
      Gene Expr Patterns. 2008 Jul;8(6):397-403. (PMID: 18539546)
      Diabetes. 1993 Dec;42(12):1799-808. (PMID: 8243826)
      Cancer Res. 2007 Oct 15;67(20):9704-12. (PMID: 17942900)
      Proc Natl Acad Sci U S A. 2014 Jan 21;111(3):984-9. (PMID: 24395782)
      BMC Cancer. 2013 Nov 21;13:555. (PMID: 24261884)
      Biull Eksp Biol Med. 1994 Aug;118(8):160-3. (PMID: 7949038)
      Adv Pharmacol. 2015;72:53-96. (PMID: 25600367)
      Eur J Pharmacol. 2002 Jan 18;435(1):1-8. (PMID: 11790372)
      Acta Oncol. 2008;47(8):1546-50. (PMID: 18607852)
      Exp Hematol Oncol. 2020 Nov 24;9(1):32. (PMID: 33292604)
      Neuroendocrinology. 2003 May;77(5):314-23. (PMID: 12806177)
      Cancer Lett. 2014 Jun 28;348(1-2):100-8. (PMID: 24657659)
      Immunol Rev. 2020 May;295(1):5-14. (PMID: 32320073)
      Cancer Med. 2023 Jul;12(13):14498-14510. (PMID: 37199392)
      World J Gastroenterol. 2012 Jun 7;18(21):2704-11. (PMID: 22690081)
      J Physiol Pharmacol. 1998 Jun;49(2):303-10. (PMID: 9670113)
      Proc Natl Acad Sci U S A. 2011 Jul 12;108(28):11692-7. (PMID: 21709230)
      Nat Rev Neurosci. 2002 Sep;3(9):715-27. (PMID: 12209120)
      Cancer Biol Ther. 2005 Jul;4(7):753-8. (PMID: 15970706)
      Neuropharmacology. 2001 Mar;40(3):327-33. (PMID: 11166325)
      Mol Nutr Food Res. 2011 Dec;55(12):1745-58. (PMID: 21805621)
      Trends Pharmacol Sci. 1989 Oct;10(10):401-7. (PMID: 2559518)
      Nat Cell Biol. 2022 Feb;24(2):230-241. (PMID: 35145222)
      PLoS One. 2012;7(1):e29915. (PMID: 22253823)
      Can J Physiol Pharmacol. 2011 Jun;89(6):393-400. (PMID: 21762014)
      Front Physiol. 2014 Apr 24;5:159. (PMID: 24795654)
      Eur J Pharmacol. 2013 Sep 5;715(1-3):154-63. (PMID: 23748019)
      Neuroscience. 1999;93(3):1159-65. (PMID: 10473280)
      Pharmacology. 1990;41(1):49-56. (PMID: 1700446)
      Neurotoxicol Teratol. 2004 Jul-Aug;26(4):587-92. (PMID: 15203181)
      Cancer Res. 2005 Dec 15;65(24):11437-46. (PMID: 16357152)
      Nat Commun. 2016 Feb 12;7:10715. (PMID: 26869349)
      Int J Oncol. 2012 Jul;41(1):228-34. (PMID: 22470130)
      Hepatology. 2007 Mar;45(3):735-45. (PMID: 17326191)
      Autoimmunity. 2011 Sep;44(6):465-70. (PMID: 21604972)
      Theranostics. 2019 Jan 1;9(1):34-47. (PMID: 30662552)
      Auton Neurosci. 2019 Nov;221:102579. (PMID: 31445405)
      Physiol Rev. 2017 Oct 1;97(4):1619-1747. (PMID: 28954853)
      Viruses. 2021 May 23;13(6):. (PMID: 34071034)
      Exp Mol Med. 2017 May 19;49(5):e335. (PMID: 28524180)
      J Transl Med. 2013 Apr 24;11:102. (PMID: 23617850)
      World J Gastroenterol. 2004 Dec 15;10(24):3608-11. (PMID: 15534915)
      J Biol Chem. 1996 Jan 5;271(1):89-96. (PMID: 8550630)
      Neuropsychopharmacology. 2014 Aug;39(9):2211-20. (PMID: 24663011)
      FEBS Lett. 1994 Jun 13;346(2-3):257-62. (PMID: 7516897)
      Proc Natl Acad Sci U S A. 1985 Mar;82(5):1558-62. (PMID: 2983351)
      Neuroscientist. 2002 Dec;8(6):562-73. (PMID: 12467378)
      J Exp Clin Cancer Res. 2000 Sep;19(3):383-90. (PMID: 11144533)
      J Cancer. 2016 Jul 27;7(12):1716-1723. (PMID: 27698909)
      Cell. 1995 Jan 27;80(2):179-85. (PMID: 7834738)
      J Biol Chem. 2014 Aug 29;289(35):24102-13. (PMID: 25012653)
      Cancer Lett. 2001 Jan 10;162(1):27-30. (PMID: 11121859)
      Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12505-10. (PMID: 16895983)
      Int J Mol Med. 2016 Jul;38(1):305-11. (PMID: 27222045)
      Histol Histopathol. 2010 Oct;25(10):1229-38. (PMID: 20712007)
      Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2580-5. (PMID: 20133656)
      J Neurochem. 1984 May;42(5):1464-7. (PMID: 6323633)
      iScience. 2021 Oct 16;24(11):103311. (PMID: 34778730)
      Physiology (Bethesda). 2009 Jun;24:171-85. (PMID: 19509127)
      Cancer Res. 2002 Nov 15;62(22):6467-9. (PMID: 12438237)
      Annu Rev Immunol. 2018 Apr 26;36:461-488. (PMID: 29677474)
      J Androl. 2005 Jul-Aug;26(4):485-93. (PMID: 15955887)
      BMC Cancer. 2018 Mar 7;18(1):263. (PMID: 29514603)
      Biochem Pharmacol. 2004 Oct 15;68(8):1685-90. (PMID: 15451412)
      Eur J Neurosci. 2004 May;19(10):2641-9. (PMID: 15147298)
      Nature. 2008 Jan 24;451(7177):460-4. (PMID: 18185516)
      Physiol Rev. 2004 Jul;84(3):835-67. (PMID: 15269338)
      Oncogene. 2016 Jul 28;35(30):3995-4008. (PMID: 26549033)
      Carcinogenesis. 2008 Oct;29(10):1979-85. (PMID: 18310090)
      World J Gastroenterol. 2008 Dec 21;14(47):7175-82. (PMID: 19084931)
      Nat Rev Cancer. 2002 Mar;2(3):161-74. (PMID: 11990853)
      Pathol Oncol Res. 2009 Dec;15(4):645-50. (PMID: 19381877)
      Am J Physiol Cell Physiol. 2009 Jun;296(6):C1400-10. (PMID: 19357231)
      Mol Immunol. 2011 Jan;48(4):399-407. (PMID: 21112637)
      Am J Obstet Gynecol. 2007 Mar;196(3):259.e1-5. (PMID: 17346546)
      Eur J Anaesthesiol. 2005 Aug;22(8):609-15. (PMID: 16119598)
      Neuron. 1994 Jun;12(6):1207-21. (PMID: 8011335)
      Acta Neuropathol. 2014 Apr;127(4):593-603. (PMID: 24196163)
      Pharmacol Rev. 1995 Jun;47(2):181-234. (PMID: 7568326)
      Sci Rep. 2021 Mar 8;11(1):5402. (PMID: 33686135)
      Future Med Chem. 2012 Jan;4(1):107-19. (PMID: 22168167)
      Mol Interv. 2001 Oct;1(4):208-18. (PMID: 14993343)
      Nature. 1969 Nov 29;224(5222):916-7. (PMID: 5389396)
      J Transl Med. 2020 Feb 24;18(1):101. (PMID: 32093682)
      PLoS One. 2012;7(5):e37041. (PMID: 22615883)
      Breast Cancer Res Treat. 2003 Jul;80(1):63-70. (PMID: 12889599)
      J Steroid Biochem Mol Biol. 2018 Apr;178:89-98. (PMID: 29155210)
      Nature. 2021 Nov;599(7885):471-476. (PMID: 34732892)
      Int J Biochem Cell Biol. 2021 Dec;141:106116. (PMID: 34742920)
      Oncol Lett. 2021 Jun;21(6):483. (PMID: 33968199)
      Cancer. 2008 Feb 15;112(4):767-78. (PMID: 18098271)
      Pharmacol Ther. 1995;67(2):187-246. (PMID: 7494864)
      Immunohorizons. 2019 Oct 21;3(10):498-510. (PMID: 31636084)
      Physiol Rev. 1999 Jan;79(1):143-80. (PMID: 9922370)
      PLoS One. 2010 Nov 30;5(11):e14171. (PMID: 21152393)
      Adv Sci (Weinh). 2021 Sep;8(18):e2102079. (PMID: 34263559)
      Neuron. 1993 May;10(5):889-98. (PMID: 8388225)
      Future Oncol. 2010 Feb;6(2):221-8. (PMID: 20146581)
      Epilepsy Res. 2000 Dec;42(2-3):183-9. (PMID: 11074190)
    • Contributed Indexing:
      Keywords: GABA; GABA receptor; cancer; carcinogenesis; neurotransmitter
    • Accession Number:
      56-12-2 (gamma-Aminobutyric Acid)
      EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
    • Publication Date:
      Date Created: 20230518 Date Completed: 20230721 Latest Revision: 20230723
    • Publication Date:
      20250114
    • Accession Number:
      PMC10358225
    • Accession Number:
      10.1002/cam4.6102
    • Accession Number:
      37199392